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We consider this to be a unique opportunity for countries in 
the Region of the Americas to develop, strengthen, and 
improve surveillance systems for congenital anomalies and 
teratogen information services. Creating health needs 
assessment tools for low- and middle-income countries may 
help them to develop effective policies to ensure primary, 
secondary, and tertiary prevention measures for congenital 
anomalies. Such initiatives will be useful for ZIKV congen-
ital syndrome control and also for having a much wider 
impact on a significant proportion of preventable and man-
ageable congenital conditions.
Keywords Zika virus; microcephaly; epidemiological 
surveillance; Americas.
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ABSTRACT
The Zika virus (ZIKV) was identified in 1947 in the Zika 
forest in Uganda, but recently it has emerged as a public 
health threat. The first evidence of human infection occurred 
in 1952, but only in April 2007 was the first outbreak in 
humans recognized. In the Americas, a ZIKV outbreak 
began in Brazil in 2015, and from the second half of 2015 
onward, a substantial number of newborns with severe 
microcephaly began to be reported to health authorities. In 
February 2016, the World Health Organization (WHO) 
declared that the clusters of microcephaly cases in areas 
affected by ZIKV constituted a Public Health Emergency of 
International Concern. Seldom has there been such a result-
ingly vast production of scientific literature in record time. 
In this report we discuss the impact of ZIKV infection 
during pregnancy, the diagnosis and surveillance of micro-
cephaly, the recognition of a clinical phenotype of ZIKV con-
genital infection, and opportunities for public health action. 
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On 1 February 2016, the World Health Organization 
(WHO) declared that the clusters of microcephaly 
cases and other neurological disorders such as 
Guillain-Barré syndrome in some areas affected by 
Zika virus (ZIKV) constituted a Public Health 
Emergency of International Concern (PHEIC) (1). “The 
increased prevalence of microcephaly at birth is partic-
ularly alarming, because it is a painful burden on the 
families and communities,” pointed out WHO 
Director-General Margaret Chan (2).
The Zika virus was identified in the 1940s in the Zika 
forest in Uganda in monkeys. The first evidence of in-
fection in humans occurred in 1952. Some five decades 
later, the international community recognized that the 
first ZIKV outbreak in humans had occurred in April 
2007 in Yap, one of the states of the Federal States of 
Micronesia, in the Pacific Ocean. At that time, the 
transmission was reported in 10 other Pacific island 
countries and areas (3). In the Americas, the virus en-
tered through Brazil, probably in 2013 (3). By 
November 2016, 48 countries in the Americas had re-
ported autochthonous cases (4), with the Aedes aegypti 
mosquito being the most significant vector (5).
In this report we discuss the impact of ZIKV infec-
tion in pregnancy, the diagnosis and surveillance of 
microcephaly, the recognition of a clinical phenotype 
of ZIKV congenital infection, and opportunities for 
public health action in countries in the Americas.
HOW THE MICROCEPHALY OUTBREAK 
WAS DETECTED
In early 2015, Brazil’s Ministry of Health began to 
receive reports of cases of an eruptive condition of un-
known cause, especially in states in the Northeast 
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region (6), and by April 2015, ZIKV was detected in 
those patients (7). The clinical manifestations were 
mild, with many regressing spontaneously without 
any clinical intervention. From the second half of 2015 
onward, cases of newborns with microcephaly (8) and 
eye abnormalities began to be reported (9).
Microcephaly is defined as a smaller than expected 
occipital-frontal head circumference (OFHC) for 
gender and gestational age. Since the growth of the 
cranium depends on the forces of the expanding brain, 
microcephaly is a measure of brain development. 
Measurement of newborn OFHC is a screening tool for 
detecting microcephaly independently from its cause. 
This condition is a clinical finding that can manifest in 
isolation or as part of different syndromes caused by 
genetics (genetic or chromosomal) or environmental 
factors.
In Brazil, between October 2015 and November 
2016, 10 276 cases of microcephaly were reported in 
accordance with the definition of the Health 
Ministry’s surveillance protocol, which includes 
newborns and fetal losses. Of these, 3 113 (30.3%) of 
the cases remain under investigation at the time of 
this manuscript submission, 2 189 cases (21.3%) have 
been confirmed for microcephaly and/or central ner-
vous system abnormalities suggestive of congenital 
infection, and 4 974 cases were ruled out (10). In 2010, 
the Brazilian Live Birth Information System (SINASC) 
reported a prevalence of microcephaly in Brazilian 
newborns of 5.7 cases per 100 000 live births (11). 
However, according to the Latin American Network 
of Congenital Malformations (ECLAMC), in Brazil 
there had been no reliable data on microcephaly 
before the Brazilian epidemic, even for those cases 
considered to be severe. Thus, at this time, the focus 
on this anomaly could lead to overreporting and mis-
diagnosis (12).
CLINICAL PHENOTYPE AND THE 
RECOGNITION OF A NEW TERATOGENIC 
SYNDROME
In Brazil, by one year after the ZIKV outbreak, more 
the 1 500 cases of congenital microcephaly associated 
with maternal ZIKV infection had been described. The 
phenotype can be defined as an “embryo-fetal brain 
disruption sequence by the Zika virus” (EFDS-ZIKV). 
The phenotype involves severe cerebral lesions and a 
dysmorphic spectrum ranging from babies with mild/
moderate to severe microcephaly secondary to the 
brain disruption sequence, and often neurological 
signs of cortical damage such as hypertonia and ar-
throgryposis (13).
Table 1 summarizes the clinical findings (from neu-
roimaging and pathology) from the reported cases, 
most of which were autochthonous infections in Brazil. 
Two reports are directed towards the neuroimaging 
findings, and two others have relevant information 
about the fetal postmortem findings. It is now ac-
knowledged that microcephaly is perhaps only part of 
the spectrum of congenital ZIKV infection, where 
some babies born without microcephaly have mani-
fested neurological abnormalities only after the neona-
tal period (14).
EPIDEMIOLOGICAL SITUATION OF ZIKA 
VIRUS AND SURVEILLANCE SYSTEMS FOR 
CONGENITAL ANOMALIES IN THE 
AMERICAS
By November 2016, 48 countries/territories of the 
Americas had already confirmed cases of autochtho-
nous ZIKV infection (increasing from 34 at the begin-
ning of 2016). Besides Brazil (with more than 1 500 
cases), 20 countries had reported congenital syndromes 
associated with Zika virus: Colombia (58 cases); the 
United States of America (31); Guatemala (15); French 
Guiana and Martinique (14 each); the Dominican 
Republic (10); Panama (5); El Salvador and Puerto Rico 
(4 each); Plurinational State of Bolivia (3); Costa Rica, 
Honduras, Paraguay, and Suriname (2 each); and 
Argentina, Canada, Grenada, Guadeloupe, Haiti, and 
Trinidad and Tobago (1 each).
Thirteen countries/territories in the Region of 
the Americas (Brazil, Colombia, the Dominican 
Republic, El Salvador, French Guiana, Guadeloupe, 
Guatemala, Honduras, Jamaica, Martinique, Puerto 
Rico, Suriname, and Venezuela) have reported an 
excess of Guillain-Barré syndrome (GBS), with at least 
one case involving laboratorial confirmation of ZIKV 
(5, 14). Before 2015, only 11 countries in the Americas 
had a surveillance system for congenital anomalies 
(SSCA): 5 in the Andean Region and Southern Cone 
(Argentina, Brazil, Chile, Colombia, Uruguay), 3 in the 
Caribbean and Central America (Costa Rica, Cuba, 
Puerto Rico), and 3 in North America (Canada, Mexico, 
United States). After the ZIKV outbreak in 2015, 
8 countries started an SSCA program: 3 in the Andean 
Region (Ecuador, Paraguay, Peru) and 5 in the 
Caribbean and Central America (Dominica, the 
Dominican Republic, El Salvador, Nicaragua, Panama).
Other modes of transmission, such as sex, blood 
transfusions, and organ transplants, may contribute 
(albeit on a much smaller scale) to the spread of the 
disease (15).
Table 2 summarizes the main characteristics of con-
genital anomaly surveillance systems, along with the 
baseline for microcephaly prevalence at birth in Latin 
America before the ZIKV epidemic in 2015. Brazil, 
for example, has had the nationwide Live Birth 
Information System (SINASC). The certificate of live 
birth is compulsory, and the presence of congenital 
anomalies must be registered on it. It was precisely 
this system that, despite its many weaknesses (mainly 
underreporting), enabled the confirmation of the mi-
crocephaly outbreak in Brazil, which had been ini-
tially notified by pediatric neurologists. Costa Rica 
and Uruguay have had population-based systems for 
the surveillance of congenital anomalies, while other 
countries have had hospital-based systems, one of 
which includes data from various South American 
countries.
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It is important to note that in 2010 the 63rd World 
Health Assembly adopted a resolution urging coun-
tries to develop systems and to train staff in relation to 
the prevention of congenital anomalies, as well as to 
strengthen surveillance systems (16). The resolution 
also called on countries to provide appropriate health 
care for people with congenital anomalies and for their 
families. This step has been neglected in public agen-
das, despite the efforts of nongovernmental organiza-
tions, health professionals, and health authorities.
Beginning with the microcephaly outbreak in Brazil 
(6), and in accordance with WHO recommendations, 
several countries in the Americas began to implement 
actions focused on detecting ZIKV infections and mi-
crocephaly and other congenital anomalies. These ac-
tions by the ministries of health have mainly included 
training health professionals and developing and 
strengthening guidelines and registers. Another chal-
lenge has been to integrate different health functions 
that are generally conducted by separate departments 
in the health system, such as surveillance, prevention, 
and assistance related to Zika virus infections and the 
occurrence of microcephaly. The example of Brazil is 
illustrative: meetings and discussions led to produc-
tion of a publication on integrated protocols for facing 
Zika virus infections, including surveillance and man-
agement of care for pregnancies and for affected in-
fants (the latest version of this document is available 
at: http://portalarquivos.saude.gov.br/images/pdf/ 
2016 /dezembro/12/orientacoes- integradas- 
vigilancia-atencao.pdf).
PUBLIC HEALTH IMPORTANCE AND 
ACTION
The ZIKV outbreak in the Americas began in Brazil 
and has spread throughout the Region of the Americas. In 
contrast to other infections caused by arboviruses trans-
mitted by the same vector (A. aegypti), such as dengue, 
chikungunya, and yellow fever (which can be fatal), 
TABLE 1. Clinical phenotype of Zika virus embryopathy in confirmed and suspected cases 
Clinical, neuroimaging, and pathological findings
Published studies and case reports
(no. of cases)
A
(35)
B
(3)
C
(4)
D
(1)
E
(1)
F
(2)
G
(12)
H
(4)
I
(13)
J
(23)
K
(13)
Microcephaly X X X X X X X X X X NDa
Corpus callosal anomaly X ND X ND X X X ND X X X
Vermian anomaly X ND X ND ND X ND ND ND ND ND
Variable ventricular dilatation X ND X X X X X ND X X X
Cerebral calcifications X X X X X X X X X X X
Brain atrophy X ND ND ND X X ND ND ND X ND
Enlarged cisterna magna X ND ND ND ND X ND ND ND X X
Hypoplasia of the brain stem and spinal cord ND ND ND X ND ND ND ND ND X X
Neuronal migration disorders X ND X X X X X ND X X ND
Variable gliosis ND ND ND ND X ND ND X ND ND ND
Microphthalmia X ND ND ND ND ND ND ND NAb NA NA
Alterations in the macula and gross macular pigment 
mottling ND X ND ND ND ND ND ND NA NA ND
Fovea reflex loss ND X ND ND NA ND ND ND NA NA ND
Hypertonia, spasticity, seizures, hyperreflexia, 
irritability, tremors X ND ND ND NA ND ND ND NA NA X
Oligohydramnios and anhydramnios ND ND ND ND ND ND X ND NA NA ND
Abnormal arterial flow in the cerebral or umbilical 
arteries ND ND ND ND ND ND X ND NA NA ND
Intrauterine growth restriction ND ND ND ND ND ND X ND NA NA ND
Elective termination of pregnancy NA NA NA X X NA NA NA NA NA NA
Source: Prepared by the authors from information in items included in this article’s References listing and in other sources: A: (8); B: (9); C: Jouannic JM, Friszer S, 
Leparc ND, Goffart I, et al. Zika virus infection in French Polynesia. Lancet. 2016 Mar 12;387(10023):1051-2.; D: Mlakar J, Korva M, Tul N, Popović M, Poljšak-Prijatelj 
M, Mraz J, et al. Zika virus associated with microcephaly. N Engl J Med. 2016 Mar 10;374(10):951-8.; E: Driggers RW, Ho CY, Korhonen EM, Kuivanen S, Jääskeläinen 
AJ, Smura T, et al. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N Engl J Med. 2016 Jun 2;374(22):2142-51.; F: Oliveira Melo AS, 
Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio S, Bispo de Filippis AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of 
the iceberg? Ultrasound Obstet Gynecol. 2016 Jan;47(1):6-7.; G: (13); H: Martines RB, Bhatnagar J, Keating MK, et al. Notes from the field: evidence of Zika virus 
infection in brain and placental tissues from two congenitally infected newborns and two fetal losses Brazil. MMWR Morb Mortal Wkly Rep 2016;65:159–60.; 
I: Cavalheiro S, Lopez A, Serra S, Da Cunha A, da Costa MD, Moron A, et al. Microcephaly and Zika virus: neonatal neuroradiological aspects. Childs Nerv Syst. 2016 
Jun;32(6):1057-60.; J: de Fatima Vasco Aragao M, van der Linden V, Brainer-Lima AM, Coeli RR, Rocha MA, Sobral da Silva P, et al. Clinical features and neuroimaging 
(CT and MRI) findings in presumed Zika virus related congenital infection and microcephaly: retrospective case series study. BMJ. 2016 Apr 13;353:i1901.; K: van der 
Linden V, Pessoa A, Dobyns W, Barkovich AJ, Júnior HV, Filho EL. Description of 13 infants born during October 2015-January 2016 with congenital Zika virus infection 
without microcephaly at birth – Brazil. MMWR Morb Mortal Wkly Rep. 2016 Dec 2;65(47):1343–8.
a ND = not described.
b NA = not applicable.
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ZIKV has mild symptoms in the affected person but has a 
devastating teratogenic potential (17, 18). This situation is 
quite critical for families, as well as a challenge for health 
systems. The technology available has already enabled 
recognition of the genomic sequence of ZIKV, which may 
help explain the epidemiological findings and the neuro-
tropism. The surveillance systems for communicable dis-
eases are on maximum alert, and various government 
actions at the regional level have been taken in an attempt 
to reverse the current lack of data, improve information, 
and develop a common strategic plan to control the 
epidemic.
With ZIKV, there is no safe period in pregnancy, and 
babies can be adversely affected in all pregnancy tri-
mesters (13). Therefore, the WHO has issued recom-
mendations about monitoring infection by ZIKV and 
its consequences, including actions for surveillance 
and notification of cases of microcephaly and GBS. 
These recommendations differ according to a country’s 
situation: a) with epidemic transmission of ZIKV; b) 
with possible endemic transmission of the virus; c) at 
risk of transmission of the virus; and d) with no risk or 
low risk of transmission of ZIKV by vector mosquitoes.
In general, in line with recommendation that the 
WHO has made to member states, some of the indica-
tors that should be reported are: 1) number of ZIKV 
cases; 2) number of ZIKV deaths; 3) number of GBS 
cases and deaths; 4) number of microcephaly cases; 5) 
number of other anomalies; 6) number of countries 
with autochthonous transmission; and 7) number of 
newly affected countries.
In addition, cases of microcephaly should continue 
to be monitored, accuracy of OFHC measurement in 
newborns should be improved, and appropriate inter-
nationally established growth curves (such as those of 
the INTERGROWTH-21st Consortium (19)) should be 
used. Finally, in countries where the epidemic is al-
ready present, it is important to have a more sensitive 
but less specific tool to detect brain abnormalities, such 
as defining microcephaly to include head circumfer-
ence less than 2 z-scores below the mean.
Nevertheless, this more inclusive definition of 
 microcephaly cannot be generalized. In Brazil, for ex-
ample, with 3 000 000 births per year, a less strict defi-
nition of microcephaly (head circumference of 33 cm or 
less) led to a significant number of healthy babies 
being included in routine exam protocols. The health 
system almost collapsed due to thousands of babies 
being referred for clinical and laboratory protocols. 
Therefore, both the risks and the benefits of different 
criteria for inclusion of suspected cases of brain anom-
alies should be assessed separately for each country 
and each scenario. A good discussion of different diag-
nostic criteria for suspected microcephaly is given by 
Victora et al. (19).
In the countries where Zika virus infection is 
spreading, other congenital infections, such as syphi-
lis, cytomegalovirus, and toxoplasmosis, are also 
prevalent, but rarely diagnosed early. Microcephaly 
can also be secondary to prenatal alcohol consump-
tion, which is also not diagnosed in the neonatal 
period. Therefore, surveillance systems that are sensi-
tive to microcephaly will have the benefit of also diag-
nosing other preventable cases of this congenital 
defect. The focus should be on prevention, early de-
tection, and management of cases and evaluation of 
health needs to help prioritize actions. Currently, there 
are cohorts of infants and pregnant women who are 
being followed very closely by the health systems of 
different countries in the Americas. This active search 
for congenital anomalies will uncover many more 
cases of microcephaly and other abnormalities that 
would otherwise be missed. Upon being detected by 
the health system, the babies and their families should 
be able to count on specific early diagnosis, in line 
with the Convention on the Rights of Persons with 
Disabilities (20).
The Latin American Network of Congenital 
Malformations (ECLAMC) is taking the first steps to 
form a regional surveillance network that aims to: a) 
disseminate, via a Web page, the base frequencies of 
congenital anomalies at birth and b) provide statistical 
programs that any person or ministry of health can use 
to analyze temporal (epidemic) or geographical (en-
demic) frequencies (12). In response to the WHO reso-
lution on birth defects (16), another initiative involves 
specific courses directed to Latin American countries 
on surveillance of birth defects and prematurity 
(see, for example: http://www.paho.org/clap/index.
php?option=com_content&view=article&id=421: 
comprometidos-en-la-prevencion-y-vigilancia-de-
anomalias-congenitas-y-partos-prematuros&Itemid= 
354&lang=en).
It is important to ensure that all these activities help 
develop local efforts that work toward recognizing 
congenital anomalies and their causes, as well as train-
ing experts in disabilities and rehabilitation. One in-
strument that might help low- and middle-income 
countries in these endeavors is the Health Needs 
Assessment Toolkit for Congenital Disorders, which 
was developed by the PHG Foundation and is freely 
available (http://www.bornhealthy.org/toolkit.html).
CONCLUSIONS
Seldom has there been in the scientific literature 
such vast production in record time as has occurred 
with the congenital ZIKV infections and the micro-
cephaly outbreak in Brazil. From the detection of cases 
of embryopathy by ZIKV, it is possible to delve into the 
etiology of microcephaly and other congenital anoma-
lies. The neurological findings described initially may 
be the tip of the iceberg. We consider this to be a unique 
opportunity to develop, strengthen, and improve the 
surveillance systems for congenital anomalies, as well 
as teratogen information services, in the Region of the 
Americas. This will help develop knowledge on poten-
tial new and emerging teratogenic agents, and help 
establish networks to monitor indicators of progress in 
each country.
WHO has started coordinating ef forts to define the 
congenital Zika virus syndrome and has issued an 
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open invitation to all partners to join in this effort (21). 
Creating health needs assessment tools for low- and 
middle-income countries may help to develop effec-
tive policies to ensure primary, secondary, and tertiary 
prevention measures for congenital anomalies. In ad-
dition, until a ZIKV vaccine is available, an informed 
society is the best ally in effectively acting on vector 
control and protecting individuals. Also critical is an 
intersectoral policy related to housing, sanitation sys-
tems (especially for quality water supply and garbage 
collection), and health care. These kinds of initiatives 
will be useful for ZIKV congenital syndrome control, 
and they can also have a much wider impact on a sig-
nificant proportion of preventable and manageable 
congenital conditions.
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El virus del Zika (ZIKV) se identificó en 1947 en el bosque de Zika, en 
Uganda, pero recientemente ha surgido como una amenaza para la salud 
pública. Los primeros datos de la infección en seres humanos surgieron en 
1952, pero no fue hasta abril del 2007 que se reconoció el primer brote en 
seres humanos. En la Región de las Américas, en el 2015 se inició un brote 
del virus en el Brasil, y desde la segunda mitad de ese año en adelante se 
empezó a notificar a las autoridades de salud un número considerable de 
recién nacidos con microcefalia grave. En febrero del 2016, la Organización 
Mundial de la Salud (OMS) declaró que los conglomerados de casos de 
microcefalia detectadas en las zonas afectadas por el ZIKV constituían una 
emergencia de salud pública de importancia internacional. Raramente ha 
habido una consiguiente producción tan vasta de publicaciones científicas 
en un tiempo récord. En este informe se aborda la repercusión de la infec-
ción por el ZIKV durante el embarazo, el diagnóstico y la vigilancia de la 
microcefalia, el reconocimiento de un fenotipo clínico de la infección con-
génita por el ZIKV y las oportunidades para las intervenciones de salud 
pública. Consideramos que se trata de una oportunidad única para los 
países de la Región de las Américas de desarrollar, fortalecer y mejorar los 
sistemas de vigilancia de las anomalías congénitas y los servicios de infor-
mación sobre teratógenos. La creación de herramientas de evaluación de 
las necesidades de salud para los países de ingresos bajos y medianos 
puede ayudarles a elaborar políticas eficaces destinadas a asegurar medi-
das preventivas primarias, secundarias y terciarias para las anomalías 
congénitas. Dichas iniciativas serán útiles para el control del síndrome 
congénito del ZIKV y también para tener una incidencia mucho mayor 
sobre una proporción significativa de las enfermedades congénitas preve-
nibles y controlables.
La infección por el 
virus del Zika y las 
anomalías congénitas 
en la Región de las 
Américas: 
oportunidades para la 
acción regional
Palabras clave
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O vírus Zika (ZIKV) foi identificado em 1947 em animais na floresta de 
Zika, em Uganda, mas se tornou um grande risco à saúde pública nos últi-
mos anos. A primeira evidência de infecção humana data de 1952, porém o 
primeiro surto em seres humanos foi registrado somente em abril de 2007. 
Na Região das Américas, o Brasil registrou um surto de zika em 2015 e, a 
partir de meados daquele ano, passou a ser notificado aos órgãos de saúde 
um número considerável de casos de recém-nascidos com microcefalia 
grave. Em fevereiro de 2016, a Organização Mundial da Saúde (OMS) 
decretou que a concentração de casos de microcefalia nas áreas de ocorrên-
cia de zika representava uma situação de emergência em saúde pública de 
interesse internacional. Raras vezes se viu tamanha produção de conheci-
mento científico em tão pouco tempo. Este artigo examina as consequên-
cias da infecção pelo vírus Zika durante a gestação, discorre sobre o 
 diagnóstico e a vigilância de casos de microcefalia e a identificação de um 
fenótipo clínico da infecção congênita pelo ZIKVS e aponta oportunidades 
Infecção pelo vírus Zika 
e malformações 
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Américas: 
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para ação em saúde pública. Os autores consideram ser esta uma opor-
tunidade única aos países da Região das Américas de expandir a capacidade 
e reforçar e melhorar a qualidade dos sistemas de vigilância de malfor-
mações congênitas e os serviços de informação sobre teratogenicidade. 
Desenvolver instrumentos para avaliar as necessidades em saúde dos 
países de baixa e média renda pode favorecer a formulação de políticas 
eficazes que garantam medidas de prevenção primária, secundária e ter-
ciária de malformações congênitas. Tais iniciativas possibilitariam o con-
trole da síndrome congênita do zika e também poderiam repercutir mais 
amplamente em um conjunto importante de afecções congênitas que 
podem ser prevenidas e controladas.
